Entrada TherapeuticsTRDA +1.54%23 Quick Ratio is 13.90 as of Mar. 2026, which is 21% above its 10-year median of 11.52. GuruFocus rates TRDA with a GF Score™ of 23/100 and a GF Value™ of $0.92 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,416 Biotechnology companies, Entrada Therapeutics ranks better than 85.59% on this metric.
Entrada Therapeutics has a quick ratio of 13.90. It generally indicates good short-term financial strength.
The historical rank and industry rank for Entrada Therapeutics's Quick Ratio or its related term are showing as below:
TRDA'
s Quick Ratio Range Over the Past 10 Years
Min: 2.32 Med: 11.52 Max: 44.46
Current: 13.9
During the past 7 years, Entrada Therapeutics's highest Quick Ratio was 44.46. The lowest was 2.32. And the median was 11.52.
TRDA's Quick Ratio is ranked better than 85.59% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs TRDA: 13.90
Entrada Therapeutics (NAS:TRDA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Entrada Therapeutics Quick Ratio Related Terms
Entrada Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Entrada Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Entrada Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entrada Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Entrada Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Entrada Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entrada Therapeutics (TRDA) has a Quick Ratio of 13.90 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Entrada Therapeutics and its competitors. This is 21% above median its historical median of 11.52. Over the past decade, Entrada Therapeutics' Quick Ratio has ranged from 2.32 to 44.46. According to the industry distribution chart, Entrada Therapeutics ranks #204 out of 1416 companies in the Biotechnology industry, placing it in the top 14.4%.
Is Entrada Therapeutics' Quick Ratio too high?
Entrada Therapeutics' current Quick Ratio of 13.90 is 21% above median its 10-year median of 11.52. Over the past 10 years, this metric has ranged from a low of 2.32 to a high of 44.46. The Biotechnology industry median Quick Ratio is 3.60. Entrada Therapeutics' value of 13.90 is 286.1% above this industry median. Based on the distribution chart, Entrada Therapeutics ranks #204 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Entrada Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entrada Therapeutics' Quick Ratio compare to SABS and ACIU?
According to the Biotechnology industry distribution chart, Entrada Therapeutics ranks #204 out of 1416 companies for Quick Ratio. This places Entrada Therapeutics in the top 14% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Entrada Therapeutics' value of 13.90 is 286.1% above this benchmark. Historically, Entrada Therapeutics' own Quick Ratio has ranged from 2.32 to 44.46 over the past decade. While the company's 10-year median is 11.52 vs. the industry median of 3.60, Entrada Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entrada Therapeutics's current Quick Ratio of 13.90 is 286.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Entrada Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entrada Therapeutics's current Quick Ratio is 13.90, which is 21% above median its own 10-year median of 11.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entrada Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Entrada Therapeutics (TRDA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.92, compared to a current price of $7.25 — trading 688% above its estimated fair value. The current Quick Ratio is 13.90, which is 21% above median its 10-year median of 11.52 and 286.1% above the Biotechnology industry median of 3.60. Entrada Therapeutics' overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Entrada Therapeutics (TRDA), the current Quick Ratio is 13.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Entrada Therapeutics (TRDA) Overvalued in 2026?
Based on GuruFocus' analysis, Entrada Therapeutics stock appears to be overvalued.
The current stock price of $7.25 is trading 688% above its estimated GF Value™ of $0.92.
GuruFocus considers Entrada Therapeutics to be Significantly Overvalued.
Key valuation signals for TRDA:
Quick Ratio: 13.90 (21% above median its 10-year median of 11.52)
GF Value™: $0.92 vs. price of $7.25 (688% above fair value)
Industry Position: 286.1% above the Biotechnology median (#204 of 1416)
No single metric tells the full story. See the TRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
23GF Score
Get the complete analysis for TRDA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRDA has been successfully added to your 
